Patient Safety & Systems-Based Practice

Polypharmacy and deprescribing in older adults

Clinical Overview and When to Suspect Polypharmacy

— Polypharmacy = concurrent use of ≥5 chronic medications; "hyperpolypharmacy" ≥10

— Affects ~40% of US adults ≥65; rises to >65% in nursing home residents

— Includes Rx, OTC (PPIs, NSAIDs, antihistamines), herbals, and supplements — always reconcile all four categories

— Polypharmacy is the single most modifiable driver of adverse drug events (ADEs), falls, delirium, and hospital readmission in older adults

— Each additional medication raises ADE risk ~7–10%; ≥5 meds doubles fall risk

— Drives a "prescribing cascade" — new symptom from drug A treated with drug B (e.g., CCB → edema → furosemide → incontinence → oxybutynin → delirium)

— New geriatric syndrome (falls, confusion, incontinence, anorexia, weight loss) within weeks of any med change

— Hospital discharge with >2 new medications added

— Multiple prescribers/pharmacies, "brown bag" mismatch with chart

— Nonadherence, cost complaints, or pill-burden fatigue

— Use of any Beers Criteria high-risk drug (benzos, anticholinergics, sliding-scale insulin, long-acting sulfonylureas, NSAIDs in CKD)

— Ask at every visit: "Bring all bottles, including OTC and supplements"

— Apply STOPP/START (Screening Tool of Older Persons' Prescriptions / to Alert to Right Treatment) and Beers 2023 at least annually

— Match each drug to an active, documented indication with time-limited goal

Board pearl: A new symptom in an older adult is a drug side effect until proven otherwise — and the correct first step is usually deprescribing the offending agent, not adding another medication. On CCS, before ordering workup for new dizziness, urinary frequency, or confusion in a polypharmacy patient, review the med list and stop the likely culprit first.

Definition and scope

Why Step 3 cares

When to suspect a polypharmacy problem

Framework for evaluation

Presentation Patterns and Key History

— Recurrent falls in patient on ≥4 CNS-active drugs (opioid + benzo + SSRI + gabapentin)

— Acute confusion 1–3 days after adding diphenhydramine, oxybutynin, or TCA

— Orthostatic syncope after intensification of antihypertensives (often BP target too tight for age)

— Hypoglycemia on glyburide or sliding-scale insulin in frail elder with poor PO intake

— GI bleed on aspirin + NSAID + SSRI without PPI

— Hyponatremia from thiazide + SSRI + PPI combination

— Brown bag review: have patient bring every bottle, OTC, eye drops, topicals, inhalers, supplements

— Reconcile against EMR; ~50% of older adults have ≥1 unreconciled medication

— Ask: "Who prescribed this? When? Is the original reason still active? Have you noticed any side effects?"

— Screen for nonadherence non-judgmentally: "Many people miss doses — how often does that happen for you?"

— Functional/cognitive context: ADLs, IADLs, prior MoCA, who manages the pillbox

— Social: cost ("Do you skip doses due to cost?"), pharmacy count, caregiver involvement

— Goals of care: life expectancy, time-to-benefit of preventive meds (statins, bisphosphonates, tight A1c)

— Anticholinergics (cumulative ACB score ≥3 → cognitive decline)

— Benzodiazepines and Z-drugs (zolpidem)

— Opioids, especially with concurrent benzo (FDA black box)

— PPIs >8 weeks without indication

— Long-acting sulfonylureas (glyburide)

— NSAIDs in CKD/HF/anticoagulated patients

Key distinction: Symptoms attributed to "aging" (fatigue, forgetfulness, unsteady gait, dry mouth, constipation) are frequently iatrogenic in polypharmacy patients. The time correlation between drug initiation and symptom onset is the highest-yield piece of history — always anchor each complaint to the medication timeline before launching diagnostic workup.

Classic polypharmacy presentations on Step 3

History-taking essentials

Red-flag medication classes to probe specifically

Physical Exam Findings and Functional Assessment

— Orthostatic vitals: supine, then 1 and 3 min standing; drop ≥20 SBP / ≥10 DBP or symptoms = positive

— Resting HR and rhythm (bradycardia from BB + donepezil + diltiazem combo)

— Weight trend (anorexia from SSRIs, metformin, digoxin)

— Hydration status (dry mucosa from anticholinergics + diuretics)

— Mini-Cog or MoCA — anticholinergic burden may shave 2–4 points

— Gait speed <0.8 m/s or Timed Up and Go ≥12 sec → high fall risk

— Pupil size (miosis with opioids, mydriasis with anticholinergics)

— Tremor, rigidity, bradykinesia — drug-induced parkinsonism from metoclopramide, antipsychotics, prochlorperazine

— Asterixis (hepatic or uremic encephalopathy from accumulated drugs)

— Bradyarrhythmia, prolonged QT (citalopram >20 mg, methadone, ondansetron, fluoroquinolones)

— Bibasilar crackles or peripheral edema from NSAIDs, pioglitazone, amlodipine

— Distended bladder (anticholinergic urinary retention)

— Fecal impaction (opioids, calcium, iron, anticholinergics)

— Epigastric tenderness, melena (NSAID/SSRI/antiplatelet)

— Bruising on anticoagulants/antiplatelets — assess fall risk vs. AFib stroke risk

— Xerostomia, candidiasis from inhaled steroids without spacer

— Vision, hearing, footwear, home hazards

— Pillbox demonstration — can the patient open bottles and read labels?

Step 3 management: When the exam shows orthostasis + cognitive slowing + dry mouth + constipation in an older adult on ≥5 meds, do not order a tilt-table or CT head first. Instead, review the medication list, stop or reduce the highest-risk agents (anticholinergics, antihypertensives, sedatives), and reassess in 1–2 weeks — this is both the diagnostic and therapeutic step.

Targeted exam in suspected polypharmacy harm

Neurologic and cognitive

Cardiovascular

GI/GU

Skin and mucosa

Functional/safety screen

Diagnostic Workup — Reconciliation Tools and Initial Labs

— Step 1: complete brown-bag reconciliation across all prescribers, pharmacies, OTC, herbals

— Step 2: apply a validated tool

— Beers Criteria (AGS 2023) — drugs to avoid in ≥65

— STOPP/START v3 — explicit start and stop rules

— Anticholinergic Cognitive Burden (ACB) scale — total ≥3 = concern

— Medication Appropriateness Index (MAI) — 10-question per-drug audit

— Step 3: assign each drug an indication, goal, duration, and stop criterion

— BMP: hyponatremia (thiazide, SSRI, carbamazepine, PPI), hyperkalemia (ACEi/ARB + spironolactone + K-supplement + NSAID), AKI (NSAID, ACEi, diuretic "triple whammy")

— CBC: anemia from chronic NSAID/antiplatelet GI loss

— CMP/LFTs: statin hepatotoxicity (rare; routine LFTs not required), acetaminophen overdose risk if >3 g/day in elder

— TSH: amiodarone, lithium

— B12: chronic metformin or PPI use ≥2 years

— Magnesium: chronic PPI use

— A1c: if <6.5% in frail elder on insulin/SU → deintensify (target 7.5–8.5% per ADA/AGS)

— eGFR: redose or stop renally cleared drugs (gabapentin, metformin, DOACs, atenolol, digoxin)

— INR: warfarin with new antibiotic, amiodarone, or NSAID

— Digoxin level: if symptomatic or new AKI

— QTc if on ≥2 QT-prolonging agents (citalopram, ondansetron, methadone, azoles, FQs, antipsychotics)

— HR if on rate-control combinations

CCS pearl: On a CCS case with a polypharmacy elder, order "medication reconciliation" as an explicit action, plus BMP, eGFR, CBC, and a targeted ECG. Do not reflexively add a brain MRI or tilt-table; advance the simulated clock after stopping the suspect agent and re-examine the patient before pursuing expensive workup.

The medication review IS the diagnostic test

Targeted labs based on the regimen

ECG

Advanced Assessment — Geriatric Syndromes and Prognosis Tools

— Indicated for patients with ≥1 geriatric syndrome (falls, frailty, delirium, incontinence, weight loss, polypharmacy itself)

— Domains: medical, functional, cognitive, psychosocial, nutritional, environmental

— Strongest evidence: reduces inappropriate prescribing, falls, and nursing home placement

— Delivered by interdisciplinary team (MD, RN, pharmacist, PT/OT, SW)

— Clinical Frailty Scale (Rockwood, 1–9) — score ≥5 = mildly frail; deprescribe aggressively

— FRAIL scale (Fatigue, Resistance, Ambulation, Illness, Loss of weight)

— Frailty changes the time-to-benefit calculus: if life expectancy < time-to-benefit, deprescribe

— Statin for primary prevention: ~2.5 years

— Tight glycemic control (microvascular benefit): ~8 years

— Bisphosphonates for fracture prevention: ~12–18 months

— Antihypertensives for stroke prevention: ~1.7 years

— Colon cancer screening benefit: ~10 years

— If estimated survival < time-to-benefit → stop the preventive med

— ePrognosis.org, Lee/Schonberg indices for community-dwelling elders

— Useful to justify deprescribing statins, ASA primary prevention, intensive A1c targets, cancer screening

— Strong evidence (Cochrane): clinical pharmacist intervention reduces inappropriate prescribing and ADEs

— Bill under Medicare Annual Wellness Visit, MTM (Medication Therapy Management), or TCM (Transitional Care Management) codes

Board pearl: In an 88-year-old with metastatic cancer and 6-month prognosis, stopping the statin is the correct answer — a randomized trial (Kutner 2015) showed statin discontinuation at end of life improves quality of life without increasing mortality. Apply the time-to-benefit principle whenever a stem flags limited life expectancy.

Comprehensive Geriatric Assessment (CGA)

Frailty assessment

Time-to-benefit anchors (memorize)

Life-expectancy estimators

Pharmacist-led medication review

The Deprescribing Framework — Stepwise Logic

— 1. Ascertain all drugs and indications (brown bag + reconciliation)

— 2. Assess overall risk of drug-induced harm (number of meds, Beers/STOPP hits, frailty, comorbidity, prior ADE)

— 3. Assess each drug for deprescribing eligibility

— No valid indication, or indication resolved

— Part of a prescribing cascade

— Harm > benefit at current age/frailty

— Symptomatic drug with no symptom relief

— Preventive drug whose time-to-benefit exceeds life expectancy

— 4. Prioritize — start with highest-harm, lowest-benefit drugs first

— 5. Implement and monitor — taper when needed, document, follow up in 1–4 weeks

— Benzodiazepines: reduce 10–25% every 2–4 weeks

— SSRIs/SNRIs: taper over 2–4+ weeks (discontinuation syndrome)

— Opioids: 10% per week typical; slower if long-term

— Beta-blockers: rebound tachycardia/ischemia

— Gabapentinoids, clonidine, PPIs (rebound acid), corticosteroids (HPA suppression if >3 weeks)

— Statins, bisphosphonates, vitamins, NSAIDs, antihistamines, anticholinergics for bladder, sliding-scale insulin

— Frame as a therapeutic trial of stopping: "Let's pause this for a month and see if you feel the same or better"

— Document patient goals (longevity vs. quality vs. symptom control)

— Reassure: deprescribing is not abandonment — it is active care

Step 3 management: Tackle one drug at a time (or one drug class) so you can attribute any change to the specific deprescription. Schedule follow-up within 2–4 weeks of each change, monitor target symptoms and withdrawal effects, and document the rationale in the chart.

Definition: deprescribing = planned, supervised dose reduction or discontinuation of medications that may cause harm or no longer provide benefit, aligned with patient goals

Five-step deprescribing algorithm (Scott/Reeve)

Drugs that need a taper (never abrupt stop)

Drugs that can usually be stopped abruptly

Shared decision-making

High-Yield Targets — Drugs to Deprescribe and How

— Beers: avoid in ≥65 (falls, fractures, MVAs, delirium, dependence)

— Taper 10–25% every 1–2 weeks; offer CBT-I as first-line for insomnia

— Adjuncts: melatonin, sleep hygiene; avoid diphenhydramine substitution

— Oxybutynin → switch to mirabegron or behavioral therapy

— Diphenhydramine, hydroxyzine → stop; substitute non-sedating antihistamine if needed

— TCAs for neuropathy → switch to duloxetine or gabapentin (renally dosed)

— Paroxetine (highly anticholinergic SSRI) → switch to sertraline or escitalopram

— Step down to H2 blocker or on-demand; full stop after 2–4 weeks of dose reduction

— Maintain indefinitely if: Barrett, bleeding ulcer history, chronic NSAID + risk factor, severe esophagitis

— Stop in CKD (eGFR <60), HF, anticoagulated, age >75

— Substitute acetaminophen ≤3 g/day, topical diclofenac, PT, duloxetine

— Switch to glipizide or DPP-4 inhibitor; deintensify A1c target to 7.5–8.5% in frail elders

— USPSTF 2022: do not initiate in adults ≥60; individualize 40–59 only if 10-yr ASCVD ≥10% and low bleed risk

— Deprescribe existing primary-prevention ASA in older adults at bleed risk

— Boxed warning: increased mortality; attempt taper after 3 months of behavioral stability

Board pearl: When the stem features an older adult with insomnia, CBT-I beats any pill — the wrong answers are diphenhydramine, zolpidem, lorazepam, mirtazapine. The right answer is CBT-I or sleep hygiene first.

Benzodiazepines / Z-drugs (zolpidem, eszopiclone)

Anticholinergics

PPIs >8 weeks without indication

NSAIDs

Long-acting sulfonylureas (glyburide) and sliding-scale insulin

Statins for primary prevention with life expectancy <2.5 years or age >75 without ASCVD — discuss stopping

Aspirin for primary prevention

Antipsychotics in dementia (BPSD)

Bisphosphonates after 5 years (oral) or 3 years (IV) if low fracture risk (drug holiday)

Prescribing Cascades — Recognize and Reverse

— CCB (amlodipine) → peripheral edema → loop diuretic → incontinence/falls

— Fix: switch to ACEi/ARB or reduce CCB dose; stop loop

— NSAID → hypertension → antihypertensive added

— Fix: stop NSAID; BP often normalizes

— Donepezil → bradycardia/syncope → pacemaker considered

— Fix: reassess donepezil benefit; check HR before AChE inhibitor

— Donepezil → urinary urgency → oxybutynin → cognition worsens (antagonistic action!)

— Fix: stop oxybutynin; behavioral therapy or mirabegron

— Metoclopramide/antipsychotic → parkinsonism → levodopa added

— Fix: stop the offending dopamine antagonist

— Thiazide → hyperuricemia/gout → allopurinol started

— Fix: switch antihypertensive class if feasible

— SSRI → SIADH/hyponatremia → fluid restriction or salt tabs

— Fix: switch SSRI or discontinue

— Opioid → constipation → laxatives → impaction; opioid → nausea → ondansetron → QT prolongation

— PPI → hypomagnesemia → muscle cramps → quinine/magnesium chronic

— Gabapentin → edema/sedation → diuretic + falls

— Inhaled anticholinergic (tiotropium) → urinary retention in BPH → tamsulosin, then orthostasis

— For every "new" symptom, ask: "What did we start, change, or increase in the last 1–3 months?"

— Reverse the cascade upstream rather than adding downstream agents

Key distinction: A prescribing cascade is iatrogenic disease, not a new diagnosis. The correct Step 3 answer is almost always to stop the upstream drug, not to start a workup or another medication. The classic dyad — amlodipine + furosemide in an older adult with edema and falls — should immediately trigger you to discontinue the diuretic and downshift the CCB.

Definition: a side effect of drug A is misinterpreted as a new disease, prompting prescription of drug B. Classic Step 3 traps:

Cascade examples to memorize

Diagnostic move

Renal and Hepatic Considerations in the Older Adult

— GFR declines ~1 mL/min/year after age 40; serum creatinine underestimates true impairment due to reduced muscle mass

— Use eGFR (CKD-EPI 2021, race-free) or measured/estimated CrCl for drug dosing

— Cystatin C–based eGFR if frail/sarcopenic and dosing is critical

— Metformin: hold if eGFR <30; reassess if 30–45

— DOACs: apixaban dose-adjust (2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5); avoid dabigatran <30; rivaroxaban/edoxaban <15

— Gabapentin/pregabalin: reduce dose; common cause of sedation and falls in CKD

— Atenolol, sotalol, digoxin: renally cleared — prefer metoprolol; digoxin level if eGFR drops

— NSAIDs: avoid in eGFR <60; "triple whammy" with ACEi + diuretic → AKI

— Spironolactone: hyperkalemia risk; avoid if eGFR <30 or K >5

— Bisphosphonates: avoid oral if eGFR <30–35

— Allopurinol: start 50–100 mg, titrate by eGFR to urate goal

— Antibiotics: nitrofurantoin avoid <30; renally dose cephalosporins, FQs, TMP-SMX (watch K)

— Avoid or reduce: acetaminophen >2 g/day in cirrhosis, NSAIDs (bleeding/HRS), benzos (use lorazepam/oxazepam/temazepam — no Phase I metabolism), opioids (reduce; avoid codeine, tramadol), statins (rosuvastatin/pravastatin safer)

— Warfarin: low INR threshold for bleeding; consider DOAC if Child A

— ↑ fat → prolonged half-life of lipophilic drugs (diazepam, amiodarone)

— ↓ total body water → higher peaks of hydrophilic drugs (lithium, digoxin)

— ↓ serum albumin → more free drug (phenytoin, warfarin)

Step 3 management: Recheck eGFR at every visit for older patients on renally cleared drugs, and especially after any acute illness, contrast, or new diuretic/ACEi. A 10–20% drop in eGFR is enough to trigger redosing of DOACs, gabapentin, and metformin.

Renal physiology of aging

Renally cleared drugs requiring dose adjustment or avoidance

Hepatic impairment

Volume of distribution changes

Transitions of Care and High-Risk Subpopulations

— ~50% of older adults have ≥1 medication discrepancy at discharge

— ~20% experience an ADE within 30 days post-discharge

— Mandatory steps:

— Reconcile pre-admission, inpatient, and discharge lists side by side

— Explicitly list what was added, stopped, and changed with rationale

— Stop "transient" inpatient meds (sliding-scale insulin, PPI started for stress ulcer prophylaxis, sleep meds, scheduled opioids)

— Provide written instructions in plain language with teach-back

— Schedule post-discharge visit within 7–14 days (Transitional Care Management billing)

— Communicate directly with PCP and outpatient pharmacist

— CMS F-tag 758: facilities must justify all psychotropics and attempt gradual dose reductions (GDR)

— Avoid PRN antipsychotics for "agitation" — try behavioral first

— Anticholinergic burden directly accelerates decline

— Cholinesterase inhibitors + anticholinergic bladder agents = pharmacologic tug-of-war — pick one

— Memantine, donepezil: reassess benefit yearly; deprescribe if severe dementia (FAST 7) or no functional benefit

— Stop: statins, bisphosphonates, ASA primary prevention, vitamins, antihypertensives (often), anti-dementia drugs, oral hypoglycemics

— Continue/optimize: analgesics, antiemetics, anxiolytics, bowel regimen

— Less relevant here, but in caregiver-elder dyads, beware shared OTC use (e.g., grandparent giving child's cough syrup or vice versa)

CCS pearl: On a CCS hospital discharge, explicitly enter "medication reconciliation" and "schedule follow-up in 7–14 days" as orders. Stop the stress-ulcer PPI, the inpatient zolpidem, and the sliding-scale insulin before the patient leaves — these are common silent contributors to readmission.

Hospital discharge — the highest-risk polypharmacy moment

Nursing home / long-term care

Dementia / cognitive impairment

End-of-life and hospice

Pregnancy and pediatrics

Complications and Adverse Drug Events

— ADEs cause ~30% of hospital admissions in older adults

— Top culprit classes (4 drugs cause ~67% of emergency hospitalizations per Budnitz NEJM): warfarin/DOACs, insulin, oral antiplatelets, oral hypoglycemics

— Falls and fractures: BZDs, opioids, antihypertensives (especially after intensification), SSRIs, antipsychotics, alpha-blockers, gabapentinoids

— Delirium: anticholinergics, benzos, opioids (esp. meperidine), corticosteroids, H2 blockers, antihistamines

— Bleeding: anticoagulant + antiplatelet + NSAID + SSRI; missing PPI in high-risk combo

— Hypoglycemia: glyburide, basal-bolus insulin with poor PO, missed meals; nocturnal hypoglycemia presenting as morning confusion or falls

— AKI: NSAID + ACEi/ARB + diuretic "triple whammy"; contrast in dehydrated patient on metformin

— Hyponatremia: thiazide + SSRI + carbamazepine; PPIs contribute

— Hyperkalemia: ACEi + ARB + spironolactone + K-supplement + TMP-SMX

— QT prolongation/TdP: citalopram >20 mg in ≥60, methadone, ondansetron, azoles, FQs, antipsychotics

— Serotonin syndrome: SSRI/SNRI + tramadol/linezolid/MAOI/triptan/methylene blue

— Anticholinergic toxicity: dry, hot, red, blind, mad — urinary retention, ileus, delirium

— C. difficile: PPI + recent antibiotic

— Osteoporosis/fracture: chronic PPI, SSRI, corticosteroids, aromatase inhibitors

— Suspected serious ADE → MedWatch (FDA Form 3500); vaccine ADE → VAERS

Board pearl: Citalopram dose cap is 20 mg/day in adults ≥60 because of QT prolongation. A stem with an 80-year-old started on citalopram 40 mg who develops syncope is a TdP/QT question — the answer is reduce dose, check QTc, and stop other QT-prolonging agents.

Magnitude of the problem

Major syndromes

Reporting

When to Escalate — Hospitalization and Specialist Involvement

— Symptomatic bradycardia, syncope with ECG abnormalities, or new arrhythmia

— Severe hypoglycemia (<54 mg/dL) or unresolved despite oral carbs

— Acute delirium with safety risk or unclear etiology

— AKI with hyperkalemia, acidosis, or volume overload

— GI bleed, intracranial bleed on anticoagulation

— Serotonin syndrome, NMS, severe anticholinergic toxidrome

— Suspected overdose (intentional or accidental)

— Suicidal ideation related to substance/medication misuse

— Warfarin bleed: 4-factor PCC + IV vitamin K

— Dabigatran: idarucizumab

— Apixaban/rivaroxaban: andexanet alfa (or PCC if unavailable)

— Opioid: naloxone; lower doses in opioid-tolerant elders to avoid withdrawal

— Benzodiazepine: flumazenil only if iatrogenic acute overdose in benzo-naive — avoid in chronic users (seizure risk)

— Digoxin: digoxin immune Fab (DigiFab) for life-threatening toxicity or K >5

— Beta-blocker / CCB: glucagon, IV calcium, high-dose insulin euglycemia

— Acetaminophen: N-acetylcysteine per Rumack-Matthew (use 4-hour level)

— TCA: sodium bicarbonate for QRS >100 ms

— Clinical pharmacist for comprehensive medication review — strongest evidence base for reducing inappropriate prescribing

— Geriatrics for frailty, dementia with BPSD, recurrent falls, or complex deprescribing

— Palliative care for end-of-life deprescribing and symptom-focused regimens

— Psychiatry for benzodiazepine or opioid tapers with comorbid anxiety/PTSD

— Cardiology, nephrology, endocrine as targeted

Step 3 management: For an older adult with new delirium on multiple psychoactive meds, admit, hold all non-essential medications, and treat the underlying syndrome (often a "drug holiday" plus rehydration) rather than adding haloperidol or quetiapine.

Indications for ED/hospital admission

Reversal agents to know

Specialist consults

Key Differentials — Adverse Drug Event vs. New Disease (Same Category)

— Drug-induced delirium (anticholinergics, BZDs, opioids, steroids, H2RAs, fluoroquinolones) — acute, fluctuating, inattention

— Major neurocognitive disorder (dementia) — chronic, progressive

— Depression-related pseudodementia — apathy, "I don't know" answers, intact reversal cues

— Hypoactive delirium from sepsis or metabolic — often missed; check infection, glucose, Na, NH3

— Differentiator: time course + reversibility with drug withdrawal

— Orthostasis from antihypertensives, alpha-blockers, diuretics, antidepressants

— Vasovagal, arrhythmia (BB + CCB + digoxin combinations cause bradyarrhythmia), mechanical (gait/vision)

— Hypoglycemia from insulin/SU

— Differentiator: orthostatic vitals, ECG, glucose at the time of event

— Drug-related: metformin, SSRIs, digoxin, opioids (nausea), bisphosphonates (esophagitis)

— Disease: malignancy, depression, thyroid, dental

— Differentiator: temporal relation to drug start

— Drug-induced retention (anticholinergics, opioids, CCBs) vs. BPH/prolapse

— Drug-induced incontinence (diuretics, alpha-blockers in women, AChEi) vs. detrusor overactivity

— Differentiator: bladder scan, drug timeline

— SIADH from SSRI/carbamazepine/PPI vs. thiazide-induced vs. true SIADH from malignancy/CNS

— Differentiator: urine osm, urine Na, uric acid, drug history

Key distinction: Drug-induced syndromes typically have a clear temporal trigger (within days–weeks of starting or up-titrating a med) and resolve with discontinuation. New primary disease is more insidious and persists despite stopping. Always run the "drug-first" differential before pursuing imaging or invasive workup.

Cognitive change in an older adult on polypharmacy

Falls / syncope

Weight loss / anorexia

Urinary symptoms

Hyponatremia

Key Differentials — Other-Category Mimics

— Frailty/sarcopenia mimics drug-induced fatigue and weight loss

— Hearing/vision loss mimics dementia and contributes to falls; check sensory before blaming meds

— Untreated pain mimics depression, agitation, "drug-seeking"

— Constipation/urinary retention mimics abdominal pathology

— Sleep apnea mimics sedation from sleep meds

— Hypothyroidism → fatigue, constipation, cognitive slowing (common in elders, especially on amiodarone, lithium)

— B12 deficiency from chronic metformin or PPI → neuropathy, cognitive decline, anemia

— Hyponatremia/hypercalcemia/uremia → confusion

— Adrenal insufficiency from chronic steroid taper too fast

— UTI or pneumonia in elders often presents as delirium or falls — do not anchor on med list alone; check UA, CBC, CXR, lactate

— Endocarditis or osteomyelitis as occult source of weight loss

— Late-life depression presents with somatic complaints and cognitive complaints — screen with PHQ-2/9

— Alcohol use disorder is under-recognized in elders (CAGE, AUDIT-C); interacts with sedatives, anticoagulants, acetaminophen

— Aortic stenosis → exertional syncope (not antihypertensive)

— Carotid sinus hypersensitivity, postprandial hypotension

— Subdural hematoma after falls on anticoagulant — low-threshold CT head

— Unintentional weight loss >5% in 6–12 months in elders → age-appropriate cancer screening if life expectancy supports it

Board pearl: The "delirium in a polypharmacy elder" question requires you to work up infection and metabolic derangements in parallel with medication review. The right answer is usually a combined approach — labs, UA, CXR, and stopping the offending drug — not either alone.

Geriatric syndromes that masquerade as ADEs (and vice versa)

Endocrine and metabolic mimics

Infectious mimics

Psychiatric

Structural/cardiovascular

Cancer

Secondary Prevention and Long-Term Medication Strategy

— Each chronic med should have: clear indication, defined goal, monitoring plan, time-to-benefit estimate, and stop criterion

— Document at every annual visit: "Continue, modify, or stop?"

— Statins: continue secondary prevention indefinitely (post-MI, CVA, PAD) unless terminal; stop primary prevention if life expectancy <2.5 yr or age >75 with no ASCVD

— Antihypertensives: SBP goal <130 for most ambulatory elders per SPRINT, but liberalize to <150 in frail, demented, or fall-prone; avoid dual ACEi/ARB

— Aspirin: continue for secondary prevention (post-MI, stroke, stent); do not start for primary prevention ≥60

— Anticoagulation for AFib: CHA₂DS₂-VASc ≥2 men / ≥3 women → DOAC preferred over warfarin; reassess yearly with HAS-BLED — high bleed score is not an automatic stop, it identifies modifiable factors

— Diabetes: ADA/AGS A1c targets — 7.0–7.5% healthy elder, 7.5–8.0% complex, <8.5% very complex/frail; avoid hypoglycemia

— Bisphosphonates: drug holiday after 5 yr oral / 3 yr IV if low fracture risk

— PPI: indication-driven; stop after 8 weeks if no high-risk indication

— Annual influenza

— RSV ≥75 (or 60–74 if high risk) — single dose, shared decision

— Pneumococcal (PCV20 or PCV15→PPSV23) per ACIP

— Zoster (Shingrix) — 2-dose series ≥50

— COVID-19 per current ACIP

— Tdap booster q10y

— Exercise (especially resistance/balance for fall prevention), nutrition, weight, smoking, alcohol, sleep hygiene, social engagement

Step 3 management: At every annual wellness visit, perform a formal medication review, update vaccines, reassess A1c/BP/lipid targets against frailty and life expectancy, and document one deprescribing or de-intensification action when applicable — this is both quality-measure-aligned and exam-aligned.

The "appropriate prescribing" mindset

Preventive meds — when to continue vs. stop

Vaccines (often forgotten on med list)

Lifestyle counseling — always on the list

Follow-Up, Monitoring, and Counseling

— 1–2 weeks for high-risk taper (BZD, opioid, beta-blocker, antihypertensive) — phone or visit

— 2–4 weeks for most deprescribing actions to assess withdrawal, rebound, return of symptoms

— 3 months to confirm sustained benefit and decide on next deprescribing target

— Antihypertensive reduction: home BP log, orthostatics

— Diabetes deintensification: A1c at 3 months, CGM or fingersticks initially

— Anticoagulant changes: INR (warfarin) at 3–5 days; renal function for DOACs q6–12 months

— Statin discontinuation: lipid panel at 6–12 weeks if rationale was tolerance

— BZD/opioid taper: withdrawal symptoms (CIWA-style screen), sleep, anxiety, function

— PPI taper: rebound dyspepsia, alarm features

— Antipsychotic taper in BPSD: behavior log, caregiver report

— "What" is changing, "why," "what to watch for," "what to do if it returns"

— Provide written med list with start date, indication, and stop date when applicable

— Synchronize refills to one pharmacy; consider blister packs or smart pillboxes

— Engage caregivers and family with patient consent

— Annual Wellness Visit (AWV) — Medicare benefit; includes med review

— Medication Therapy Management (MTM) — Medicare Part D benefit for ≥3 chronic conditions / ≥8 meds / ≥$5330 spending (thresholds update)

— Transitional Care Management (TCM) — billable 7- or 14-day post-discharge visit

— Chronic Care Management (CCM) — monthly care coordination for ≥2 chronic conditions

CCS pearl: Always schedule a specific follow-up interval after a deprescribing change on CCS (e.g., "Office visit in 2 weeks"), order interval labs (BMP, A1c, INR as relevant), and re-examine the patient before advancing the case. Skipping the recheck is a common error penalized in CCS scoring.

Post-deprescribing follow-up cadence

What to monitor (drug-specific)

Counseling structure (use teach-back)

System-level supports

Ethical, Legal, and Patient Safety Considerations

— Treat stopping a drug like starting one: explain rationale, risks, benefits, alternatives

— Document shared decision-making; respect patient preference to continue if they understand the risk

— For preventive meds at end of life, frame around goals of care rather than "giving up"

— Capacity is decision-specific; a patient with mild dementia may still consent to deprescribing if they can communicate choice, understand info, appreciate consequences, and reason

— Involve surrogate (DPOA-HC) when capacity is lacking; check for advance directive and POLST/MOLST

— Suspected elder abuse/neglect (including caregiver withholding or diverting meds) → report to Adult Protective Services (state-specific; most states mandate physician reporting)

— Suspected diversion of controlled substances → check state PDMP every Rx; document

— Impaired driver due to sedatives/cognition: state-specific reporting (e.g., CA mandates DMV report for dementia; others permit)

— FDA boxed warning: concurrent opioid + benzo increases overdose death; if unavoidable, lowest effective doses, naloxone co-prescription, PDMP review, urine drug screen

— Document medical necessity and risk-mitigation steps

— Discharge medication errors are a leading cause of 30-day readmission

— Use teach-back, written reconciled list, follow-up appointment, and direct communication with the receiving clinician (PCP, SNF MD)

— Stop inpatient-only meds (PPI for stress ulcer prophylaxis, scheduled hypnotics, sliding-scale insulin) before discharge

— If an ADE causes harm, disclose honestly per AMA/ACP ethics; apologize, explain, and document; involve risk management early

— High pill burden disproportionately affects low-income elders; cost-related nonadherence is a safety issue — ask explicitly and use 90-day supplies, generics, $4 lists, mail-order

Board pearl: A confused elder who "refuses" deprescribing without understanding the risks does not automatically retain the medication — assess capacity for that decision and involve surrogate if needed. Conversely, a capacitated elder who declines deprescribing must have their choice respected and documented.

Informed consent for deprescribing

Capacity assessment

Mandatory reporting

Controlled substances and the opioid–benzo black box

Transition-of-care safety (Step 3 favorite)

Disclosure of harm

Equity and cost

High-Yield Associations and Rapid-Fire Facts

— First-gen antihistamines (diphenhydramine, hydroxyzine)

— Benzodiazepines and Z-drugs (zolpidem)

— Long-acting sulfonylureas (glyburide, chlorpropamide)

— Sliding-scale insulin as sole regimen

— Anticholinergic bladder antimuscarinics (oxybutynin IR)

— TCAs (amitriptyline, doxepin >6 mg)

— Skeletal muscle relaxants (cyclobenzaprine, carisoprodol)

— Meperidine, pentazocine

— Antipsychotics in dementia (boxed warning)

— Estrogen oral, megestrol, glyburide

— NSAIDs chronic in CKD, anticoagulated, age >75

— PPIs >8 weeks without indication

— Nitrofurantoin if eGFR <30

— Aspirin without secondary indication

— PPI for uncomplicated PUD at full dose >8 weeks

— Benzodiazepine for ≥4 weeks

— Loop diuretic for ankle edema without HF/CKD/cirrhosis

— Two drugs from same class (two NSAIDs, two SSRIs)

— Statin in established ASCVD or diabetes >40

— ACEi in HFrEF, post-MI, diabetic nephropathy

— Anticoagulation for AFib with CHA₂DS₂-VASc ≥2

— Calcium + vitamin D + bisphosphonate in osteoporosis

— SABA/LABA-ICS appropriately in COPD/asthma per GOLD/GINA

— Diphenhydramine + elderly = delirium

— Glyburide + missed meal = severe hypoglycemia

— NSAID + ACEi + diuretic = AKI (triple whammy)

— SSRI + NSAID = GI bleed (add PPI or change)

— Amlodipine + furosemide = prescribing cascade for ankle edema

— Citalopram >20 mg in ≥60 = QT prolongation

— Chronic PPI = ↓ Mg, ↓ B12, ↑ C. diff, ↑ fracture, ↑ CAP

— Tramadol + SSRI = serotonin syndrome + seizures

— Anticholinergic + AChE inhibitor = self-defeating Rx

Key distinction: Beers is "avoid" criteria; STOPP is explicit stop criteria; START is explicit start criteria. Boards may ask which framework justifies a specific recommendation — match the verb to the tool.

Beers high-risk drugs — memorize

STOPP highlights

START highlights (drugs that should be added)

Rapid associations

Board Question Stem Patterns

— Stem: 78-year-old on amlodipine for HTN develops ankle edema, started on furosemide, now has urinary incontinence and a fall

— Best next step: stop furosemide, reduce or switch amlodipine (not urology referral, not oxybutynin)

— Stem: 82-year-old started on diphenhydramine for sleep develops acute confusion

— Best next step: stop diphenhydramine; counsel sleep hygiene/CBT-I

— Distractor: head CT, haloperidol, donepezil

— Stem: elder on lorazepam + oxycodone + sertraline + gabapentin presents after fall

— Best next step: deprescribe sedatives (taper benzo first), PT, vitamin D, home safety

— Stem: 84-year-old with metastatic pancreatic cancer, 4-month prognosis, on atorvastatin for primary prevention

— Best next step: stop the statin (time-to-benefit > life expectancy)

— Stem: frail 86-year-old with A1c 6.2% on glyburide and basal insulin; recurrent hypoglycemia

— Best next step: stop glyburide, reduce insulin, target A1c 7.5–8.5%

— Stem: 75-year-old on omeprazole for 5 years for "stomach pain," now with hypomagnesemia

— Best next step: taper and stop PPI, repeat Mg; address true indication

— Stem: 68-year-old asks about starting aspirin; no ASCVD

— Best next step: do not start (USPSTF 2022)

— Stem: 80-year-old on citalopram 40 mg with syncope; QTc 510

— Best next step: reduce to ≤20 mg, stop other QT drugs, check Mg/K

— Stem: elder discharged on 14 meds including new PPI, zolpidem, and sliding-scale insulin

— Best next step: stop the inpatient-only meds, reconcile, schedule 7-day follow-up

Step 3 management: When two answer choices both look reasonable — one orders a workup and one stops a medication — in a polypharmacy elder, the deprescribing answer is usually correct.

Pattern 1 — The cascade

Pattern 2 — The anticholinergic delirium

Pattern 3 — The fall on multiple CNS-active meds

Pattern 4 — Statin at end of life

Pattern 5 — Diabetes overtreatment

Pattern 6 — PPI taper

Pattern 7 — Aspirin primary prevention in elder

Pattern 8 — Citalopram QT

Pattern 9 — Discharge reconciliation

One-Line Recap

In every older adult on ≥5 medications, treat the medication list itself as the most likely diagnosis: at each encounter, reconcile every drug (Rx, OTC, herbal), match each to an active indication and a time-to-benefit that fits the patient's prognosis, apply Beers/STOPP/START to identify high-risk and missing drugs, and deprescribe one agent at a time with a planned taper, monitoring labs, and follow-up in 1–4 weeks — because in this population, the right intervention is almost always to subtract a drug rather than to add one.

Board pearl: When in doubt on a Step 3 question about a confused, falling, hyponatremic, hypoglycemic, or AKI-prone elder on a long med list, the highest-yield answer choice is the one that stops, tapers, or substitutes an offending agent — not the one that orders another test or adds another drug.

The five-step deprescribing engine: ascertain all drugs → assess harm risk → assess each drug for eligibility → prioritize highest-harm/lowest-benefit → implement with taper and follow-up.

The four "always look for" cascades: CCB→edema→loop; NSAID→HTN→antihypertensive; AChEi→urgency→anticholinergic; antipsychotic/metoclopramide→parkinsonism→levodopa — reverse upstream, not downstream.

The time-to-benefit anchors that drive end-of-life deprescribing: statin 2.5y, tight A1c 8y, bisphosphonate 12–18mo, BP control 1.7y, colon screening 10y — if prognosis < benefit horizon, stop the preventive med.

The Step 3 safety triad: brown-bag reconciliation at every visit, 7–14 day post-discharge follow-up with explicit stop of inpatient-only meds, and at least one documented deprescribing or de-intensification action per annual wellness visit when indicated.